Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236018 | 0.89 | ALDH1A1 (0.50) | CA1CA2CA9KCNA5ALDH1A1 | |
| SCHEMBL4245385 | 0.82 | RAB9A (0.46) | CA1CA2CA9KCNA5ALDH1A1 | |
| SCHEMBL4247417 | 0.81 | ALDH1A1 (0.53) | CA1CA2CA9ALDH1A1MEN1 | |
| SCHEMBL4248727 | 0.80 | ALDH1A1 (0.50) | KCNA5ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL2210786 | 0.77 | KCNA5 (0.67) | KCNA5ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL4244514 | 0.74 | HTT (0.55) | CA1CA2KCNA5RAB9ANPC1 | |
| SCHEMBL4242916 | 0.71 | CHRNB2 (0.46) | CA1CA2CA9KCNA5ALDH1A1 | |
| SCHEMBL4245434 | 0.71 | KCNA5 (0.46) | KCNA5ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL4626781 | 0.70 | HTT (0.68) | KCNA5ALDH1A1KMT2ARAB9ANPC1 | |
| SCHEMBL28573216 | 0.69 | CA2 (0.70) | CA1CA2CA9ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | CA1 2291/4885CA2 1130/4885CA9 4067/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | CA1 2293/4885CA2 1135/4885CA9 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.